Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Zevra Therapeutics and keeping the price target at $26.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Folkes has given his Buy rating due to a combination of factors surrounding Zevra Therapeutics’ performance and strategic positioning. The company has demonstrated robust growth in the U.S. market for its product, Miplyffa, and is advancing towards potential approval in the European Union, which presents a significant revenue opportunity not yet reflected in the current stock valuation. Zevra is financially stable, reducing the likelihood of needing additional funding to pursue its strategic goals, including the EU market entry, which it may manage independently or through partnerships.
Moreover, Zevra’s recent progress includes filing a marketing authorization application with the European Medicines Agency for arimoclomol, marketed as Miplyffa, for Niemann-Pick disease type C. The company’s ability to convert patients from its Expanded Access Program to paying customers in the U.S. suggests potential for similar success in Europe. With a larger and more established market in the EU, Zevra’s efforts could lead to substantial revenue contributions, further supporting the Buy rating as these opportunities are currently underappreciated in the stock’s valuation.